BioScrip surges on M&A speculation following CVS Coram acquisition

|By:, SA News Editor

BioScrip (BIOS +18.5%) shares surge following renewed M&A speculation on the back of this morning's CVS acquisition of Coram for $2.1B.

Market chatter is referencing Jefferies' opinion the BioScrip could realistically fetch $12-$14/share, an 83% premium from the current price.

The stock has been downtrodden as of late, with shares having fallen 66.5% into yesterday's close from June highs.